Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.
暂无分享,去创建一个
A. Matakidou | L. Siu | Z. Ghazoui | R. Mesía | R. Raja | H. Mann | J. Fayette | D. Zandberg | S. Wildsmith | M. D. L. Reyes | C. Barker | J. Whiteley | N. Morsli | Weimin Li | Qu Zhang | Han Si | Magdalena Wrona